U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta (LLY)

Eli Lilly and Company LLY today announced that the U.S. District Court for the Southern District of Indiana has issued an order that prohibits the remaining defendants in the Cymbalta® (duloxetine hydrochloride) patent litigation from selling a generic duloxetine product in the United States during the term of the Cymbalta compound patent. The patent provides protection for Cymbalta until at least June of 2013.